The Constraint
Conventional targeted therapies miss ~80% of disease-relevant proteins
•Dependent on pre-existing, detectable ligand binding sites,
•Untapped target space leaves tremendous unmet need
The Gap
Current IP/TPD screening approaches are expensive and carry high-risk
•High-throughput screening campaigns consume significant time and resources, with no guarantee for success
The Opportunity
A systematic framework for IP/TPD drug discovery doesn't exist yet
•We need a platform to enable rational design and engineering of novel functional protein interactions
Why Now
Three fields have matured — and only now are powerful enough to combine
The convergence of these technologies enables our approach, aimed to unlock targets previously deemed undruggable
Structural Biology
Atomic-resolution understanding of molecular interfaces and dynamic conformations has uncovered new biology.
Induced Proximity
FDA-approved PROTACs and molecular glues proved that induced proximity produces real therapeutic outcomes.
AI/ML for Biology
Automated analysis, predictive modeling, and agentic AI workflows have empowered scientists to do more with their data
Our Platform
ARC-Engine:
A single platform.
Multiple therapeutic Applications
Analyze
Builds a comprehensive view of the protein interaction landscape to reveal opportunities invisible to conventional approaches.
Resolve
Identifies compatible protein pairings with the highest potential for programmable biological control.
Construct
Translates platform insights into therapeutic candidates designed for precision and purpose.
Closed-loop learning:
The platform learns from every experiment, improving discovery speed and candidate quality over time.
